a1D-Adrenoceptors are responsible for the high sensitivity and the slow time-course of noradrenaline-mediated contraction in conductance arteries.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Flacco N
  • Parés J
  • Pérez-Aso M
  • Noguera MA
  • Ivorra MD
  • McGrath JC

Abstract

The objective of this study was to determine whether the different time-course characteristics of a1-adrenoceptor-mediated contraction in arteries can be related to the subtypes involved. Contractile responses to noradrenaline (NA) were compared with inositol phosphate accumulation and extracellular signal-regulated kinase (ERK)1/2 phosphorylation after a1-agonist stimuli in the same vessels in the presence or absence of a1-antagonists in rat or in a1-subtype knockout (KO) mice. Aorta, where a1D-AR is the main functional subtype, had higher sensitivity to NA (in respect of inositol phosphate [IP], pERK1/2, and contractile response) than tail artery, where the a1A-adrenoceptor subtype is predominant. Furthermore, the contraction in aorta exhibited a slower decay after agonist removal and this was consistent in all strains harboring a1D-adrenoceptors (from rat, a1B-KO, and wild-type [WT] mice) but was not observed in the absence of the a1D-adrenoceptor signal (a1D-adrenoceptor blocked rat aorta or aorta from a1D-KO). IP formation paralleled a1-adrenoceptor-mediated contraction (agonist present or postagonist) in aorta and tail artery. High sensitivity to agonist and persistence of response after agonist removal is a property of a1D-adrenoceptors. Therefore, the preponderance of this subtype in noninnervated conductance arteries such as aorta allows responsiveness to circulating catecholamines and prevents abrupt changes in vessel caliber when the stimulus fluctuates. Conversely, in innervated distributing arteries, high local concentrations of NA are required to activate a1A-adrenoceptors for a response that is rapid but short lived allowing fine adjustment of the contractile tone by perivascular sympathetic nerves.

Datos de la publicación

ISSN/ISSNe:
2052-1707,

Pharmacology research & perspectives  Wiley-Blackwell Publishing Ltd

Tipo:
Article
Páginas:
-
PubMed:
25505555

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • conductance and resistance vessels, contraction time-course, a1A-adrenoceptors

Proyectos y Estudios Clínicos

ENCCA—EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS

Investigador Principal: ADELA CAÑETE NIETO

261474_ENCCA_PE_CAÑETE . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2011

ESTUDIO ABIERTO, MULTICENTRICO Y ALEATORIZADO EN FASE II PARA EVALUAR LA ADICION DE BEVACIZUMAB A LA QUIMIOTERAPIA EN NIÑOS Y ADOLESCENTES CON DIAGNOSTICO INICIAL DE SARCONA METASTASICO DE TEJIDOS BLANDOS, RABDOMIOSARCOMA Y NO-RABDOMIOSARCOMA.

Investigador Principal: JOSÉ MARÍA FERNÁNDEZ NAVARRO

BO20924 . 2010

ESTUDIO EN FASE III, ABIERTO, ALEATORIZADO, DE CARFILZOMIB FRENTE A MEJOR TRATAMIENTO DE SOPORTE EN PACIENTES CON MIELOMA MULTIPLE REFRACTARIO Y RECIDIVANTE.

Investigador Principal: ISIDRO JARQUE RAMOS

PX-171-011 . 2011

ESTUDIO EN FASE II, CIEGO-SIMPLE, RANDOMIZADO, CONTROLADO CON PLACEBO, PARA ESTUDIAR LA EFICACIA Y LA SEGURIDAD DEL NANOBODY ANTI-FACTOR VON- WILLEBRAND ADMINISTRADO COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON PURPURA TROMBOCITOPENICA TROMBOTICA ADQUIRIDA .

Investigador Principal: JAVIER DE LA RUBIA COMOS

ALX-0681-2.1/10 . 2011

ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, ABIERTO, PARA COMPARAR LA EFICACIA Y LA SEGURIDAD DE LA POMALIDOMIDA EN COMBINACIÓN CON DOSIS BAJAS DE DEXAMETASONA FRENTE A DOSIS ALTAS DE DEXAMETASONA EN PACIENTES CON MIELOMA MÚLTIPLE REFRACTARIO O REC IDIVANTE Y REFRACTARIO.

Investigador Principal: ISIDRO JARQUE RAMOS

CC-4047-MM-003 . 2011

ESTUDIO DE FASE III MULTICENTRICO Y ALEATORIZADO DE COMPARACION DE CARFILZOMIB, LEANLIDOMIDA Y DEXAMETASONA (CRD) CON LENALIDOMIDA Y DEXAMETASONA (RD) EN PACIENTES CON MIELOMA MULTIPLE RECIDIVADO.

Investigador Principal: ISIDRO JARQUE RAMOS

PX-171-009 . 2011

PROTOCOLO EUROPEO DE TRATAMIENTO PARA EL NEUROBLASTOMA DE RIESGO BAJO O INTERMEDIO.

Investigador Principal: ADELA CAÑETE NIETO

LINES . 2011

Cita

Compartir